| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/17/2005 | US20050037330 Composition for maintaining organ and cell viability |
| 02/17/2005 | US20050037200 Bilayered, stabilized lipids and microemulsion; for prevention of AIDS |
| 02/17/2005 | US20050037096 Dispersed solid-containing complex carbohydrate |
| 02/17/2005 | US20050037093 Treatment of nail infections with no |
| 02/17/2005 | US20050037088 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/17/2005 | US20050037087 Microcapsular composition comprising core, including at least one active ingredient in combination with an oil or mixture of oils, wherein oils alone or in combination with active ingredient have specific gravity higher than that of water; microcapsules can be easily isolated by precipitation |
| 02/17/2005 | US20050037086 Continuous-flow method for preparing microparticles |
| 02/17/2005 | US20050037085 Microencapsulated DNA for vaccination and gene therapy |
| 02/17/2005 | US20050037084 Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
| 02/17/2005 | US20050037083 Activating a water insoluble drug in aqueous solution; freeze drying; intravenous injection; sonicating evaporation |
| 02/17/2005 | US20050037081 Novel formulation |
| 02/17/2005 | US20050037080 Active substance such as fragrance oil, gel-forming polymer such as alginate or a pectic substance, divalent cation, preferably calcium ion, which gels gel-forming polymer, added polymer not gelled by divalent cation such as carboxymethyl cellulose, water; production requires low energy cost; efficiency |
| 02/17/2005 | US20050037079 Temperature sensitive state-changing hydrogel composition and method for preparation |
| 02/17/2005 | US20050037078 Biocompatible and biostable polyurethane based devices for the sustained delivery of drugs or other compounds in a living organism; produce local or systemic pharmacological effects |
| 02/17/2005 | US20050037077 Absorption in upper part of gastrointestinal system; microcapsules coated with hydrophilic polymer such as Eudragit |
| 02/17/2005 | US20050037076 comprising immediate release, sustained release and delayed release dosage forms, with each dosage forms having a different release profile, wherein each reaches a maximum concentration at different times |
| 02/17/2005 | US20050037075 Targeted delivery of controlled release polymer systems |
| 02/17/2005 | US20050037074 Treating adrenal dysfunction in a patient by administering a pharmaceutically effective amount of a combined glucocorticoid such as hydrocortisone and a delivery vehicle, wherein delivery vehicle provides for delayed and sustained release of glucorticoid; congenital adrenal hyperplasia |
| 02/17/2005 | US20050037073 Drug delivery; improved bioavailability of orally delivered biologically active hydrophobic compounds; self-emulsifying for forming an oil-in-water containing media with prolonged dissolution |
| 02/17/2005 | US20050037072 Pharmaceutical compositions for rectal and vaginal administration |
| 02/17/2005 | US20050037071 Oral dosage forms comprising pellets that contain, percentage-wise, a high dosage of an active drug agent, and also contain additional components such as surfactants that enhance absorption and solubility of active drug agent within gastrointestinal tract |
| 02/17/2005 | US20050037070 Acid labile proton pump inhibitor microencapsulated with material that enhances shelf-life of pharmaceutical formulation, and antacid, wherein initial serum concentration of proton pump inhibitor is greater than 0.1 mu g/ml at any time within 30 minutes after administration of pharmaceutical; shelf life |
| 02/17/2005 | US20050037069 Solid and stable creatine/citric acid composition(s) and compositions carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 02/17/2005 | US20050037068 Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs |
| 02/17/2005 | US20050037067 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds |
| 02/17/2005 | US20050037066 Formulation and manufacturing process for Coenzyme Q10 soft gel capsules |
| 02/17/2005 | US20050037065 Fatty acids from both plant and animal sources and methods for minimizing unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, nausea, or difficulty in swallowing or ingesting; for pregnant or lactating women |
| 02/17/2005 | US20050037064 Heteroxylan film-forming composition for making capsules and resulting capsules |
| 02/17/2005 | US20050037063 Combined therapies |
| 02/17/2005 | US20050037060 topical mixture of minoxidil or salts, solubilizers, solvents and cosolvents, used for the treatment of alopecia |
| 02/17/2005 | US20050037059 drug delivery device comprising release linings interposed between an outer layer having adhesive properties and an inner layer having drug impervious layers, used for drug delivery to the skins or mucous membranes |
| 02/17/2005 | US20050037055 rapid-dissolve films comprising a water soluble polyether and/or blends with hydrophilic cellulosic polymers, containing drugs or cosmetics |
| 02/17/2005 | US20050037054 Gloves containing dry powdered Aloe and method of manufacturing |
| 02/17/2005 | US20050037047 Medical devices comprising spray dried microparticles |
| 02/17/2005 | US20050037041 Controlling bleeding of lake dyes powder in aqueous solution by applying powder coating and curing |
| 02/17/2005 | US20050037040 cosmetics used for treatment of skin disorders |
| 02/17/2005 | US20050037039 Composition for treatment of tinea pedis and method of use |
| 02/17/2005 | US20050037035 comprising sphingoids used as cosmetic for topical application with animals having fur covered skins for maintaining and/or repairing the keratoseborrheaic condition of the skin and/or fur; skin disorders |
| 02/17/2005 | US20050037033 microbiocides used for preventing of sexually transmitted infections comprising ciclopirox olamine and carriers |
| 02/17/2005 | US20050037032 Composition and method of treatment for urogenital conditions |
| 02/17/2005 | US20050037031 applying to the interior of the nasal cavity a cream which physically blocks communication between the smells and the olfactory nerves in the nasal cavity; dietetics |
| 02/17/2005 | US20050037030 Stable topical formulation of clarithromycin |
| 02/17/2005 | US20050037026 such as Alzheimer's disease; amyloid precursor proteins; comprises diphtheria toxoid as carrier |
| 02/17/2005 | US20050036998 Mixture with a thixotropic gelatine carrier to form gelatin capsules; enhanced the solubility, stability and absorption |
| 02/17/2005 | US20050036984 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof |
| 02/17/2005 | US20050036983 In vivo use of water absorbent polymers |
| 02/17/2005 | US20050036978 Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| 02/17/2005 | US20050036977 Water insoluble substance complexed with ion exchange resin; rapid-disintegrating tablet/film; effervescence |
| 02/17/2005 | US20050036975 Surfactant-free shaving aid preparation |
| 02/17/2005 | US20050036960 contains a suspending agent (a clay like montmorillonite), a rinse-off resistant agent (maleic anyhydride terpolymers, polyvinylpyrillidone, and copolymers) and a skin protectant agent (oatmeal, soy, zinc oxide); free of oil and silicone |
| 02/17/2005 | US20050036954 a toothpaste, a sexual enhancement chemical compound such as sildenafil citrate, vardenafil hydrochloride or tadalafil and medicinal herbs such as catuaba, damiana, epimedium, maca and muria puama for improving sexual activity in males, in addition to enhancing oral hygiene |
| 02/17/2005 | US20050036953 Topical compositions of ammonium lactate |
| 02/17/2005 | US20050036952 Compositions and methods for the treatment of aches and pains |
| 02/17/2005 | US20050036951 Methods of treating lung diseases |
| 02/17/2005 | US20050036949 A pharmaceutical dispenser; a liquid formulation comprising nitric oxide; respiratory system diseases; atomizing |
| 02/17/2005 | US20050035177 Method for preparing colloidal solution of bismuth sodium tartrate |
| 02/17/2005 | US20050034723 Substrates for drug delivery device and methods of preparing and use |
| 02/17/2005 | US20050034720 Aerosol inhaler |
| 02/17/2005 | DE10336044A1 Tensidfreie Rasierhilfszubereitung Surfactant Rasierhilfszubereitung |
| 02/17/2005 | DE10333317A1 Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) Formulation for protein drugs without the addition of human serum albumin (HSA) |
| 02/17/2005 | DE10332011A1 Verwendung von Glaszusammensetzungen zum Erzielen eines antioxidativen Effektes Use of glass compositions to achieve an anti-oxidative effect |
| 02/17/2005 | DE10329812A1 Sustained release composition useful in the treatment of e.g. benign prostatic hyperplasia comprises Tamsulosin core with a coating containing combination of polyvinyl acetate and polyvinyl pyrrolidone |
| 02/17/2005 | CA2544240A1 Cpg-packaged liposomes |
| 02/17/2005 | CA2535045A1 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| 02/17/2005 | CA2535026A1 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 02/17/2005 | CA2534983A1 Methods and devices for the treatment of intervertebral discs |
| 02/17/2005 | CA2534971A1 5'-and 3'-capped aptamers and uses therefor |
| 02/17/2005 | CA2534693A1 Medicaments for inhalation comprising steroids and a betamimetic |
| 02/17/2005 | CA2534546A1 Novel composition |
| 02/17/2005 | CA2534484A1 Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| 02/17/2005 | CA2534480A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 02/17/2005 | CA2534471A1 Method and apparatus for producing ultrafine drug particles |
| 02/17/2005 | CA2534368A1 Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration |
| 02/17/2005 | CA2534367A1 Pharmaceutical composition containing water soluble drug |
| 02/17/2005 | CA2534157A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | CA2534132A1 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 02/17/2005 | CA2534097A1 Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator |
| 02/17/2005 | CA2533786A1 Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| 02/17/2005 | CA2533182A1 Dry syrup containing loratadine |
| 02/17/2005 | CA2533163A1 Novel compositions of sildenafil free base |
| 02/17/2005 | CA2532667A1 Semi-solid formulations for the oral administration of taxoids |
| 02/17/2005 | CA2532566A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 02/17/2005 | CA2532344A1 Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases |
| 02/17/2005 | CA2532140A1 Vaccines using pattern recognition receptor-ligand:lipid complexes |
| 02/17/2005 | CA2531032A1 Programmed immune responses using a vaccination node |
| 02/17/2005 | CA2528879A1 Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrences |
| 02/17/2005 | CA2528273A1 Hydrophilic adhesive compositions for delivery of herbal medicines |
| 02/16/2005 | EP1507005A2 Antisense modulation of BCL-X expression |
| 02/16/2005 | EP1506967A1 Dipeptidyl peptidase inhibitors |
| 02/16/2005 | EP1506786A1 Medicinal compositions containing ghrelin |
| 02/16/2005 | EP1506781A1 Vaginal care composition |
| 02/16/2005 | EP1506780A2 Pharmaceutical formulations with macrolides alone or mixed with other active agents |
| 02/16/2005 | EP1506774A1 Smooth muscle peristole inhibitor |
| 02/16/2005 | EP1506773A1 Sprayable skin protectant compositions |
| 02/16/2005 | EP1506041A1 Bisphosphonic acids for the treatment and prevention of osteoporosis |
| 02/16/2005 | EP1506032A1 Aerosol drug inhibition of lung metastases |
| 02/16/2005 | EP1506031A1 Method and apparatus for vaporizing a compound |
| 02/16/2005 | EP1506030A1 Medicament respiratory delivery device and cartridge |
| 02/16/2005 | EP1506003A1 Soluble formulations comprising insulin aspart and insulin detemir |
| 02/16/2005 | EP1505995A1 Chewable compositions containing a gel-forming extract of psyllium |